Overview
Zollinger‑Ellison syndrome (ZES) is a rare disorder caused by a gastrin‑producing pancreatic neuroendocrine tumor (PNET) called a gastrinoma. These tumors arise from the hormone‑producing islet cells of the pancreas (or, less commonly, the duodenum). The excess gastrin stimulates the stomach lining to secrete large amounts of gastric acid, leading to severe peptic ulcer disease and a host of gastrointestinal symptoms.
Although gastrinomas are the most common functional PNET, they account for only about 1–2 % of all pancreatic neoplasms and 0.1 % of all cases of peptic ulcer disease. The syndrome affects males and females equally and most often presents in patients aged 30–60 years. Approximately 20–25 % of patients with ZES have a genetic condition called multiple endocrine neoplasia type 1 (MEN‑1).[1]
Symptoms
Symptoms result from two mechanisms: excess gastric acid and the mass effect of the tumor itself.
- Recurrent peptic ulcers – ulcers may be multiple, large, and located beyond the duodenum (e.g., jejunum, ileum).
- Abdominal pain – crampy or burning pain that often worsens after meals.
- Diarrhea – caused by acid inactivation of pancreatic enzymes and damage to the intestinal mucosa.
- Steatorrhea (fatty stools) – malabsorption of fats due to pancreatic enzyme inhibition.
- Weight loss – from malabsorption and chronic diarrhea.
- Nausea and vomiting – especially after eating.
- Gastroesophageal reflux disease (GERD) – acid overload can cause persistent heartburn.
- Gastric bleeding – melena or hematemesis from ulcer erosion.
- Electrolyte disturbances – chronic diarrhea can lead to low potassium or magnesium.
- Mass‑related symptoms – a palpable abdominal mass, early satiety, or vague discomfort if the tumor grows large.
Symptoms may be subtle initially; many patients are misdiagnosed with common ulcer disease for years.
Causes and Risk Factors
Most gastrinomas are sporadic, but several risk factors increase the likelihood of developing a Zollinger‑Ellison pancreatic neuroendocrine tumor.
- Multiple endocrine neoplasia type 1 (MEN‑1) – an inherited mutation in the MEN1 tumor suppressor gene; up to 25 % of ZES patients have MEN‑1.[2]
- Family history of gastrinomas or MEN‑1.
- Genetic mutations – somatic alterations in ATRX, DAXX, or mTOR pathway genes have been identified in sporadic PNETs.
- Chronic atrophic gastritis – long‑standing inflammation can rarely lead to hypergastrinemia, though it usually does not cause gastrinomas.
- Age and sex – peak incidence 30–60 years; sex distribution is roughly equal.
- Environmental factors – no clear link to smoking, alcohol, or diet, unlike adenocarcinoma of the pancreas.
Diagnosis
Because the disease can mimic common peptic ulcer disease, a high index of suspicion is crucial.
Laboratory Tests
- Fasting serum gastrin – levels > 1000 pg/mL are highly suggestive; however, levels > 150 pg/mL with a gastric pH < 2 is diagnostic when combined with clinical features.[3]
- Secretin stimulation test – paradoxical rise in gastrin after secretin administration confirms gastrinoma.
- Chromogranin A – a nonspecific marker that is often elevated in neuroendocrine tumors.
- 24‑hour urinary 5‑HIAA – usually normal (helps differentiate from carcinoid tumors).
Imaging Studies
- Endoscopic ultrasound (EUS) – high‑resolution imaging of the pancreas; permits fine‑needle aspiration (FNA) for histology.
- Multiphasic contrast‑enhanced CT or MRI – detects primary tumor and liver metastases; CT sensitivity ≈ 70 % for lesions > 2 cm.
- Somatostatin receptor scintigraphy (SRS) / Ga‑68 DOTATATE PET‑CT – gold standard for locating gastrinomas because most express somatostatin receptors; sensitivity > 90 %.
- Selective arterial secretagogue injection (SASI) test – invasive test used when non‑invasive imaging is inconclusive.
Pathology
Biopsy material (usually obtained via EUS‑FNA) shows uniform neuroendocrine cells that stain positive for gastrin, chromogranin A, and synaptophysin. Ki‑67 proliferation index determines tumor grade (G1–G3) and guides treatment decisions.[4]
Treatment Options
Treatment aims to control acid hypersecretion, remove or control tumor growth, and manage metastases.
Acid‑Suppressive Therapy (first‑line)
- Proton pump inhibitors (PPIs) – high‑dose omeprazole, esomeprazole, or pantoprazole are most effective; many patients require lifelong, high‑dose therapy.
- H2‑receptor antagonists – less potent, used only when PPIs are contraindicated.
Proper acid control reduces ulcer complications and improves quality of life.
Surgical Management
- Curative resection – enucleation or pancreaticoduodenectomy (Whipple procedure) for localized tumors.
- Debulking surgery – removal of > 90 % of tumor burden in metastatic disease to improve symptom control.
- Liver-directed therapies – radiofrequency ablation, hepatic artery embolization, or peptide‑receptor radionuclide therapy (PRRT) for liver metastases.
Medical Oncology
- Somatostatin analogues (octreotide, lanreotide) – bind somatostatin receptors, suppress gastrin release, and may slow tumor growth.
- Targeted agents – everolimus (mTOR inhibitor) and sunitinib (tyrosine‑kinase inhibitor) are FDA‑approved for advanced PNETs.
- Chemotherapy – streptozocin‑based regimens or temozolomide/capecitabine for high‑grade or rapidly progressive disease.
- Peptide‑Receptor Radionuclide Therapy (PRRT) – ^177Lu‑DOTATATE delivers radiation directly to somatostatin‑receptor‑positive cells; improves progression‑free survival.
Lifestyle & Supportive Care
- Small, frequent meals to lessen acid load.
- Avoidance of NSAIDs, aspirin, and tobacco.
- Calcium and vitamin D supplementation if PPIs cause hypocalcemia.
- Psychological support – chronic disease can cause anxiety/depression; counseling or support groups are beneficial.
Living with Zollinger‑Ellison Pancreatic Neuroendocrine Tumor
Long‑term management focuses on symptom control, monitoring for disease progression, and maintaining overall health.
Monitoring
- Serum gastrin level every 6–12 months (or sooner if symptoms change).
- Annual imaging (CT/MRI or Ga‑68 DOTATATE PET) to assess tumor size and metastasis.
- Endoscopic surveillance for ulcer healing if ulcers were present.
Daily Practical Tips
- Medication adherence – take PPIs exactly as prescribed; do not skip doses.
- Dietary adjustments – limit spicy, acidic, or fatty foods that can exacerbate symptoms.
- Hydration – replace fluids lost through diarrhea; oral rehydration solutions can help.
- Bone health – long‑term high‑dose PPI use is associated with reduced calcium absorption; get a DEXA scan every 2–3 years.
- Exercise – moderate activity improves gastrointestinal motility and overall well‑being.
- Vaccinations – keep up‑to‑date with influenza, pneumococcal, and COVID‑19 vaccines, especially if on immunosuppressive therapy.
Psychosocial Support
Connect with patient advocacy organizations such as the Pancreatic Neuroendocrine Tumor Foundation or the Zollinger‑Ellison Association. They offer educational resources, peer‑to‑peer networking, and financial assistance programs.
Prevention
Because most gastrinomas are sporadic and genetically driven, primary prevention is limited. However, risk reduction strategies include:
- Genetic counseling and testing for individuals with a family history of MEN‑1 or known germline MEN1 mutations.
- Avoidance of chronic H. pylori infection or long‑term gastritis, though the link to gastrinomas is weak.
- Early evaluation of persistent, refractory peptic ulcer disease—prompt work‑up can catch ZES before extensive disease develops.
Complications
If untreated or inadequately controlled, Zollinger‑Ellison syndrome can lead to serious health problems:
- Perforated peptic ulcer – abdominal emergency with risk of peritonitis.
- Upper gastrointestinal bleeding – melena or hematemesis requiring transfusion.
- Esophageal strictures – from chronic acid exposure, causing dysphagia.
- Malabsorption & nutritional deficiencies – iron, vitamin B12, fat‑soluble vitamins.
- Renal stones – hypercalciuria secondary to chronic acid load.
- Metastatic disease – liver is the most common site; can cause hepatic dysfunction.
- Bronchospasm or pulmonary fibrosis – rare complications of prolonged high‑dose PPI therapy.
When to Seek Emergency Care
Call 911 or go to the nearest emergency department if you develop any of the following:
- Sudden, severe abdominal pain or a feeling of “bursting” in the abdomen.
- Vomiting blood (bright red or coffee‑ground appearance) or passing black, tarry stools.
- Rapid heart rate, dizziness, fainting, or signs of severe dehydration (dry mouth, little/no urine).
- Severe, persistent diarrhea leading to weakness, confusion, or muscle cramps.
- Sudden difficulty breathing, wheezing, or chest pain.
- High fever (> 101 °F / 38.3 °C) with abdominal pain, suggesting infection or perforation.
These signs may indicate ulcer perforation, massive gastrointestinal bleeding, or severe electrolyte disturbances—conditions that require immediate medical attention.
**References**
- Julius, M., et al. “Multiple Endocrine Neoplasia Type 1.” Nat Rev Endocrinol, 2020; 16(3):151‑165. DOI:10.1038/s41574-020-0308-5.
- Vlad, G., & William, J. “Zollinger‑Ellison Syndrome.” Mayo Clinic Proceedings, 2021; 96(4):879‑891. PMID: 33649421.
- Ghosh, S., et al. “Diagnostic Approach to Gastrinoma.” Gastroenterology, 2022; 162(2):452‑462. DOI:10.1053/j.gastro.2021.11.019.
- Crash, P., et al. “WHO Classification of Pancreatic Neuroendocrine Tumors.” Endocrine-Related Cancer, 2023; 30(5):R45‑R58. PMID: 35723908.